CSL Limited (ASX: CSL) is back in focus after UBS issued a fresh note ahead of the Company’s full-year results. The broker sees meaningful upside in its CSL share price forecast 2026 Australia in 2026, even as competitive pressure continues across key markets.
Figure 1: CSL’s Melbourne headquarters anchors its global biotech operations [Courtesy: BioSpectrum Asia]
The update matters for investors tracking ASX healthcare stocks. CSL has endured a difficult stretch, and this latest broker view offers a clearer picture of where the shares may head next.
What Happened With CSL’s FY26 Guidance
CSL disappointed the market in May with a significant earnings downgrade. The Company lowered its revenue guidance to around US$15.2 billion on a constant currency basis. Net profit guidance was cut to approximately US$3.1 billion, excluding restructuring costs and impairments.
This compares with previous guidance of US$15.6 billion in revenue and US$3.3 billion in profit. CSL also flagged about US$5 billion in write-downs to be booked across FY26 and FY27. Management said further detail would follow with the FY26 results announcement.
The Vifor Setback
CSL’s Vifor division had a difficult second half of the year. Generic competition intensified, Velphoro sales weakened, and Tavneos was withdrawn from sale. UBS said lower pricing is expected to drive a sharp margin contraction in the second half of FY26.
UBS expects margins to weaken again in FY27 as pricing pressure continues. Analysts note Tavneos contributes only around one per cent of group revenue, limiting the direct earnings impact.
UBS CSL Price Target Australia and Broker Views
Among the brokers tracking CSL, UBS stands out for its more upbeat stance. Its research note this month reaffirmed a buy rating with a clear rationale.
Figure 2: UBS signage displaying the bank’s key logo and branding [Courtesy: Shutterstock]
UBS’s Bullish Case
UBS set a price target of A$158.00 per share for CSL. At the time of the note, this implied a return of close to 37 per cent. The broker argues much of the negative sentiment around Vifor has already been priced into the shares.
UBS also pointed to encouraging signs in CSL’s core plasma business. Industry feedback suggests the core United States hospital market remains sound. CSL has reportedly gained market share recently, albeit at lower average prices.
The Broader Analyst Split
Not every broker shares the same level of conviction. Broker data shows the majority of covering analysts, 10 out of 18, sit on a hold rating for CSL. The remaining eight analysts maintain buy or strong buy recommendations.
Figure 3: A rising trend line reflects growing broker optimism on CSL [Courtesy: Magnific]
The average analyst price target across the group sits at A$138.88 per share. Morgans is also positive, maintaining a buy rating with a target of A$147.59. A small group of analysts reportedly see potential for CSL shares to reach as high as A$197.85 over the next year.
This spread of views highlights genuine uncertainty in the current CSL ASX biotech stock forecast. Investors weighing a CSL share price forecast 2026 Australia view should note this divide between bulls and holds.
CSL (ASX: CSL) Share Price Snapshot
- Last traded price: A$114.22 per share
- Market capitalisation: A$55.43 billion
- 52-week range: A$90.00 to A$275.79 per share
- UBS price target: A$158.00 per share
- Average broker price target: A$138.88 per share
- Morgans price target: A$147.59 per share
Figure 4: CSL share price [Courtesy: ASX]
CSL shares have shown volatility over the past year in line with broader ASX healthcare sector movements. The stock remains well below its 52-week high, reflecting the scale of the recent downgrades.
Industry Outlook
The global plasma therapies market continues to support long-term demand for CSL’s core products. CSL operates across more than 100 countries, giving it broad exposure to both developed and emerging healthcare markets. That global spread gives CSL an edge in the broader ASX biotech stock forecast picture, even while margins stay under near-term strain.
Future Direction and Impact on Investor Sentiment
CSL’s next set of full-year results will be closely watched by the market. A turnaround in Vifor performance, or news of new contracts, may change how investors view the stock. The interim CEO has steered the Company back toward its core plasma operations.
The impact on investor sentiment will likely hinge on evidence of earnings stabilisation. Whether cost savings can outweigh continued margin pressure will largely shape the CSL share price forecast 2026 Australia outlook.
Analysts at Macquarie Group Ltd (ASX: MQG) believe market expectations have already reset to a conservative level, which could support the shares if results modestly beat forecasts.
ALSO READ: Culpeo Minerals Launches Entitlement Issue to Fund Copper Exploration Growth in Chile
FAQ
Q1. What is UBS’s current price target for CSL shares?
Ans. UBS has set a price target of A$158.00 per share for CSL.
Q2. Why did CSL shares fall over the past year?
Ans. Earnings downgrades, leadership changes and Vifor-related impairments weighed on the share price.
Q3. What is driving the current CSL share price forecast 2026 Australia view?
Ans. Analysts are watching Vifor stabilisation, cost savings and core plasma market share gains.
Q4. Do all brokers agree on CSL’s outlook?
Ans. No. Ten of eighteen analysts rate the stock a hold, while eight maintain buy ratings.
Disclaimer
This article is meant only for informational purposes. If you are an investor watching CSL Limited closely, all data published in this content is sourced from ASX announcements and external sources. Kindly verify all information related to share price and market data independently. Any investment decision should be made at the investor’s own risk. Colitco does not hold any position in the above-mentioned Company.
Source
- https://www.fool.com.au/2026/07/25/how-high-does-ubs-think-csl-shares-will-go-2/
- https://www.fool.com.au/2026/07/20/could-csl-shares-double-from-here-heres-what-the-experts-think/
- https://kalkine.com.au/news/healthcare/can-csl-asxcsl-continue-strengthening-its-global-healthcare-leadership
- https://www.asx.com.au/markets/company/CSL
Luke Carlino is a seasoned Copywriter, Content Strategist, and Social Media Manager specialising in Mining, Finance, and Business journalism. With more than a decade of industry experience, he brings rigorous editorial standards and commercial acuity to every project.
